Technology

Filament Health has developed a groundbreaking platform with the first-ever natural psychedelic drug candidates.

To date, the healing potential of natural psychedelic drugs has not been explored due to psychedelic prohibition and a lack of botanical extraction expertise.


Our technology allows us to produce stable, standardized formulations of any psychedelic species. Our innovations have yielded patented methods to produce the world’s first pharmaceutical-grade, botanical psychedelic drug candidates.

Psilocybin mushrooms growing in the Filament Lab

Psychedelic Botanical Drug Processing Steps:

Step 1: Propagation
Grow botanical psychedelics
Trade Secrets
Step 2: extraction
beaker with leaf inside icon
Remove target compounds from biomass
Patent Families 1, 7, & 8
13 Filed 7 Granted
Step 3: Purification
beaker icon
Grow botanical psychedelics
Patent Families 2 & 6
4 Filed
Step 4: Standardization & Stabilization
scale icon
Precise and stable formulation
Patent Families 3 & 4
4 Filed
Step 5: human delivery
Pills Icon
Compositions of matter for different deliverable forms
Patent Family 5
4 Filed

Intellectual Property

Filament’s IP is a combination of trade secrets and patented technologies which provide robust protection for our candidates, and leverage the known safety profiles of classical psychedelic substances. We secure patent protection for technologies used to extract, purify, stabilize, and standardize our products, as well as for the finished formulations of the drugs we manufacture.

dried ayahuasca in pestle and mortar


Natural drug development provides an intellectual property advantage.

Unlike synthetically-derived drugs, botanical drugs are complex mixtures derived from natural sources. This complexity makes them difficult to replicate without knowledge of the exact manufacturing processes. As a result, our drug candidates have excellent protection beyond the patents we have been issued.

While there are many ways to create synthetic drugs, the methods to extract, purify, and standardize naturally-occurring psychedelic compounds are finite and therefore more readily protected with IP.

our facility

Filament’s research and development facility, operated by our wholly-owned subsidiary Psilo Scientific Ltd., is one of the first in the world to hold a Health Canada Dealer’s License and be GMP-compliant. These capabilities are required to manufacture and distribute drugs for human consumption in clinical trials or via authorized compassionate use.

Filament Health office building

Our industry-leading facility allows us to:

  • Propagate psychedelic plants and fungi
  • Conduct genetic research
  • Develop manufacturing technology
  • Generate intellectual property
  • Manufacture drug candidates for our own drug development as well as for distribution to drug developers, researchers, and other licensed parties
Image of psilocybin mushroom with an arrow pointing to the chemical structures psilocybin and psilocin
image of echinopsis peruviana and its chemical structure mescaline
Image of Acacia Simplex and its chemical structure DMT
Image of Anadenanthera Peregrina and its chemical structure Bufotenin

Filament’s research program includes all natural psychedelics: psilocybin, DMT, harmaline, mescaline, and more.

Image of psilocybin mushroom with an arrow pointing to the chemical structures psilocybin and psilocin
image of echinopsis peruviana and its chemical structure mescaline
Image of Acacia Simplex and its chemical structure DMT
Image of Anadenanthera Peregrina and its chemical structure Bufotenin

Filament’s research program includes all natural psychedelics: psilocybin, DMT, harmaline, mescaline, and more.

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.